Solesence, Inc. (SLSN) stock analysis
Close on Nov 11, 2026Market cap $64.36MP/E –Yield –
StockData Score
Prices as of Nov 11, 2026How the score works
Weak7 of 30 checks passed
Solesence passes 7 of the 30 checks behind our score; 11 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 0/6
- Growth
- 2/6
- Past performance
- 1/6
- Financial health
- 4/6
- Dividend
- 0/6
What stands out
No debt
Solesence has no borrowings on its latest balance sheet.
Earnings grew over 5 years
Net income grew 23.2% a year on average over the last five fiscal years.
Revenue growing 10%+ a year
Revenue grew 18.5% a year over the last three fiscal years.
Interest well covered
No meaningful interest expense to cover.
What to watch
Return on equity under 15%
Return on equity was -14.2% over the last twelve months and averaged -29.8% over five years; we look for 15% on both.
Return on capital under 10%
Return on invested capital was -7.3%, below the 10% that usually covers the cost of capital.
Earnings growth not accelerating
Net income grew -145% over the last twelve months, against a 5-year average of 23.2% a year.
Elevated bankruptcy risk
The Altman Z-score is -0.87; above 3 is the safe zone and below 1.8 the distress zone.
Valuation0/6
P/E against its history
Not enough price and earnings history to compare.
P/E against the industry
Needs positive earnings and enough profitable companies in the industry.
EV/EBITDA above its 5-year median
Solesence's EV/EBITDA of 1266.3 is above its 5-year median of 54.9.
P/B above the industry
Solesence's price-to-book of 4.95 is above the Soap, Detergents, and Cleaning Preparations; Perfumes, Cosmetics, and Other Toilet Preparations median of 4.86.
Price against fair value
We could not estimate a fair value: it needs at least two valuation methods with positive inputs.
Margin of safety
Depends on the fair value estimate.
Growth2/6
Revenue growing 10%+ a year
Revenue grew 18.5% a year over the last three fiscal years.
EPS growth over 3 years
Needs positive EPS three years ago and today.
Earnings growth not accelerating
Net income grew -145% over the last twelve months, against a 5-year average of 23.2% a year.
Growing slower than the industry
Revenue grew -14.0% over the last twelve months; the Soap, Detergents, and Cleaning Preparations; Perfumes, Cosmetics, and Other Toilet Preparations median is 6.0%.
Company guidance
No outlook found in earnings releases from the last twelve months.
Gross margin improving
Gross margin was 26.8% over the last twelve months, against 26.7% a year earlier.
Past performance1/6
Return on equity under 15%
Return on equity was -14.2% over the last twelve months and averaged -29.8% over five years; we look for 15% on both.
Return on capital under 10%
Return on invested capital was -7.3%, below the 10% that usually covers the cost of capital.
Return on equity below the industry
Solesence's return on equity of -14.2% is below the Soap, Detergents, and Cleaning Preparations; Perfumes, Cosmetics, and Other Toilet Preparations median of -1.2%.
Earnings grew over 5 years
Net income grew 23.2% a year on average over the last five fiscal years.
Net margin below its 5-year average
Net margin was -3.5% over the last twelve months, against a 5-year average of -1.2%.
Net margin below the industry
Solesence's net margin of -3.5% is below the Soap, Detergents, and Cleaning Preparations; Perfumes, Cosmetics, and Other Toilet Preparations median of 0.2%.
Financial health4/6
No debt
Solesence has no borrowings on its latest balance sheet.
Debt not rising
With no debt today, leverage cannot have risen.
Debt covered by cash flow
There is no debt to cover.
Interest well covered
No meaningful interest expense to cover.
Short-term assets don't cover short-term debts
Current assets are 0.97 times current liabilities.
Elevated bankruptcy risk
The Altman Z-score is -0.87; above 3 is the safe zone and below 1.8 the distress zone.
Dividend0/6
No dividend
Solesence has not paid a dividend in the last twelve months.
Yield against Treasuries
No dividend.
Yield against the market
No dividend.
Dividend stability
No dividend.
Earnings cover
No dividend.
Cash-flow cover
No dividend.
Fair value
How we estimate itWe don't publish a fair value for Solesence. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.
Valuation over time
Using the earnings and balance sheet published at each date, not today's.
- P/E at month end
- Own 5-year median 117
- Soap, Detergents, and Cleaning Preparations; Perfumes, Cosmetics, and Other Toilet Preparations median 29.9
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
High risk
- Average value traded per day
- $29.24K
- Value traded per 1% price move
- $5.82K
Downside
High risk
- Typical loss in a bad month
- 45.3%
- Volatility (annualized)
- 106%
- Sharpe ratio, 1 year
- -0.68
- Beta to the S&P 500 (5Y)
- 1.34
Typical bad-month loss, week by week
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
Operating margin
Net margin
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +18.6% | +18.5% | +29.4% | +19.7% | |
| Gross profit | +30.9% | +26.9% | +23.3% | +18.6% | |
| Operating income | +29.8% | – | +11.8% | – | |
| Net income | +155.6% | – | +23.2% | – | |
| EPS, diluted | +100.0% | – | +5.9% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -45.4% | 46.6% | 23.1% | |
| Return on assets | -27.3% | 8.6% | 6.1% | |
| Current ratio | 2.64 | 1.30 | 1.81 | |
| Debt to equity | – | 0.53 | – | |
| Net debt to EBITDA | – | 0.27× | – | |
| Interest coverage | -84.5× | 3.0× | – | |
| Inventory turnover | 10.5× | 3.2× | 3.0× | |
| Capex to revenue | 1.2% | 5.1% | – | |
| Diluted shares | 31M | 39M | 73M |
Cash use needs five years of cash flow figures
Solesence does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont analysis
Return on equity split into margin, efficiency and leverage
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 4.5% | 1.35× | 3.78× | 23.1% |
| FY2024 | 2.1% | 1.36× | 7.18× | 20.6% |
| FY2023 | -13.2% | 1.15× | 12.81× | -194.8% |
| FY2022 | -7.0% | 1.20× | 5.10× | -43.2% |
| FY2021 | 7.9% | 1.41× | 4.11× | 45.5% |
| FY2020 | 5.8% | 1.49× | 5.40× | 46.6% |
| FY2019 | -24.0% | 1.57× | 5.51× | -207.7% |
| FY2018 | -14.7% | 2.21× | 2.78× | -90.2% |
| FY2017 | -6.3% | 2.25× | 1.84× | -26.2% |
| FY2016 | -11.9% | 2.29× | 1.67× | -45.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
- ProfitableNet income above zero$2.81M
- Cash generatingOperating cash flow above zero-$8.57M
- Return on assets improvedROA up on the prior year3.5% → 6.2%
- Earnings backed by cashOperating cash flow above net income-$8.57M vs $2.81M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose0.96 → 1.81
- No dilutionShare count did not rise65M → 73M
- Gross margin improvedGross margin up on the prior year24.93% → 27.52%
- More efficientAsset turnover rose1.67 → 1.37
See a number that looks wrong?